COSTA MESA, Calif., Aug. 11, 2016 /PRNewswire-iReach/ -- WCCT Global, a full service CRO headquartered in Orange County, CA, will be featured in an upcoming publication regarding successful results from asthma clinical research conducted at their Phase I-IV Costa mesa clinical pharmacology unit. Over the years, this CPU has conducted numerous asthma clinical
Photo - http://photos.prnewswire.com/prnh/20160804/395846
This asthma clinical research program was a Phase I study in pediatric asthma patients. As a single site, WCCT enrolled 15 patients; there were no other sites involved in the study. The results of this study will be published in an upcoming edition of Allergy and Asthma Proceedings, with study title "Pharmacokinetics and pharmacodynamics of albuterol multidose dry powder inhaler and albuterol hydrofluoroalkane in asthmatic children." The overall purpose of the study was to help develop easier-to-use treatment options for children with asthma.
When asked about the company's role in this asthma clinical research program, WCCT CEO and Founder Dr. Kenneth Kim, had this to say: "The foundation of this company was built upon the successful conduct and enrollment of asthma clinical trials, and it is always a pleasure to go back to our roots and continue to make contributions to this field of study. While WCCT has expanded much since our early days, spanning multiple therapeutic areas and indications, there is perhaps no therapeutic area for which we are better equipped to conduct research at our multiple Southern California facilities than asthma." In addition to its Phase I-IV CPU, WCCT also owns and operates a clinic dedicated to asthma and allergy patients in Long Beach, CA, where additional research is performed.
About WCCT Global
WCCT Global is a multi-site, full service pharmaceutical contract research organization (CRO) of outsourced early drug development and late phase CRO services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, "With compassion for people, we strive for tomorrow's therapies to be available today" truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, patient recruitment, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Renal, and Vaccines.
Media Contact: Salvador Solis, WCCT Global, 7146881500x2261, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE WCCT Global
Subscribe to our Free Newsletters!
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...
Intermittent fasting is a complete or partial abstinence from food and caloric drinks for a ...View All